AU2021254765A1 - Pirfenidone for coronavirus treatment - Google Patents

Pirfenidone for coronavirus treatment Download PDF

Info

Publication number
AU2021254765A1
AU2021254765A1 AU2021254765A AU2021254765A AU2021254765A1 AU 2021254765 A1 AU2021254765 A1 AU 2021254765A1 AU 2021254765 A AU2021254765 A AU 2021254765A AU 2021254765 A AU2021254765 A AU 2021254765A AU 2021254765 A1 AU2021254765 A1 AU 2021254765A1
Authority
AU
Australia
Prior art keywords
approximately
pirfenidone
release
subject
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021254765A
Other languages
English (en)
Inventor
Laura AGUILAR
Estuardo Aguilar-Cordova
José Agustin Rogelio Magaña Castro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Excalibur Pharmaceuticals Inc
Original Assignee
Excalibur Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excalibur Pharmaceuticals Inc filed Critical Excalibur Pharmaceuticals Inc
Publication of AU2021254765A1 publication Critical patent/AU2021254765A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
AU2021254765A 2020-04-14 2021-04-14 Pirfenidone for coronavirus treatment Abandoned AU2021254765A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063010009P 2020-04-14 2020-04-14
US63/010,009 2020-04-14
PCT/US2021/027335 WO2021211745A1 (en) 2020-04-14 2021-04-14 Pirfenidone for coronavirus treatment

Publications (1)

Publication Number Publication Date
AU2021254765A1 true AU2021254765A1 (en) 2022-12-08

Family

ID=78084909

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021254765A Abandoned AU2021254765A1 (en) 2020-04-14 2021-04-14 Pirfenidone for coronavirus treatment

Country Status (14)

Country Link
US (1) US20230117397A1 (cg-RX-API-DMAC7.html)
EP (1) EP4135671A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023521887A (cg-RX-API-DMAC7.html)
KR (1) KR20230038644A (cg-RX-API-DMAC7.html)
CN (1) CN115916162A (cg-RX-API-DMAC7.html)
AU (1) AU2021254765A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020821A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175526A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002843A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022016155A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22087664A (cg-RX-API-DMAC7.html)
IL (1) IL297296A (cg-RX-API-DMAC7.html)
MX (1) MX2022012986A (cg-RX-API-DMAC7.html)
WO (1) WO2021211745A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
CN114796122B (zh) * 2022-03-30 2023-03-24 山东大学 一种聚多巴胺载吡菲尼酮纳米粒及其制备方法和应用
JP7845721B2 (ja) * 2022-04-29 2026-04-14 オーバーシーズ ファーマシューティカルズ リミテッド ピルフェニドンの経口用持続放出性固形製剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709178B2 (en) * 1995-09-19 1999-08-26 Intermune, Inc. Inhibition of tumor necrosis factor alpha
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20030103941A1 (en) * 2001-10-09 2003-06-05 Crombleholme Timothy M. Materials and methods for preventing or reducing scar formation
WO2005013917A2 (en) * 2003-02-28 2005-02-17 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
AP2007004244A0 (en) * 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101088557A (zh) * 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
WO2010132864A1 (en) * 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
HUE058753T2 (hu) * 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
WO2013181691A1 (en) * 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
JP7066321B2 (ja) * 2014-01-10 2022-05-13 アヴァリン ファーマ インク. エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用

Also Published As

Publication number Publication date
CL2022002843A1 (es) 2023-09-01
CN115916162A (zh) 2023-04-04
MX2022012986A (es) 2023-03-21
EP4135671A1 (en) 2023-02-22
ECSP22087664A (es) 2022-12-30
BR112022020821A2 (pt) 2022-12-20
IL297296A (en) 2022-12-01
KR20230038644A (ko) 2023-03-21
EP4135671A4 (en) 2024-08-14
US20230117397A1 (en) 2023-04-20
WO2021211745A1 (en) 2021-10-21
CA3175526A1 (en) 2021-10-21
CO2022016155A2 (es) 2022-12-20
JP2023521887A (ja) 2023-05-25

Similar Documents

Publication Publication Date Title
US20230117397A1 (en) Pirfenidone for coronavirus treatment
US20190298714A1 (en) Use of levocetirizine and montelukast to treat rhinosinusitis and nasal polyposis
AU2019328903B2 (en) Composition for eradicating Helicobacter pylori
US20230058134A1 (en) Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
US12064509B2 (en) Enema for rectal application
CA3190278A1 (en) Antiviral use of liraglutide and gefitinib
JP2010083871A (ja) 抗アデノウイルス剤を含有する医薬組成物
CN101966190A (zh) 一种治疗高血压含氨氯地平和依普罗沙坦的复方制剂
US20230181582A1 (en) Compositions and methods for treating lung injuries associated with viral infections
JP2004331660A (ja) 医薬組成物
HK40094222A (en) Amiselimod for preventing, treating, or ameliorating ulcerative colitis
CN119139378A (zh) 神香草挥发油及包含其的组合物在制备治疗特发性肺纤维化药物中的应用
US20230310467A1 (en) PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19
CN121868290A (zh) 深海丁内酯类化合物在制备预防和/或治疗高尿酸血症和/或尿酸性肾病产品中的应用
KR20150063040A (ko) 간 질환의 치료에 사용하기 위한 메타독신 및 메타독신 연장 방출성 제제
TW202143985A (zh) 治療之方法
CN105362226A (zh) 氨溴索沙丁胺醇气雾剂的制备方法
CN114377005A (zh) 泽兰黄酮在制备抗高尿酸血症和抗痛风药物中的应用
CN102552257A (zh) 一种含有盐酸雷尼替丁和曲昔派特的复方制剂及其用途
HK1199815B (en) Levocetirizine and montelukast for the treatment of influenza and common cold
JP2009143965A (ja) 医薬組成物
CN105434412A (zh) 氨溴索沙丁胺醇控释胶囊
JP2010106012A (ja) 抗アデノウイルス剤及びそれを含有する医薬組成物
CN101766634A (zh) 氨溴索多西环素复方制剂

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period